クラスとしてのGLP-1受容体アゴニストと結腸直腸がんのリスクとの関連性:遡及的なコホート研究のメタ解析
Ying Zhong1, Tingting Wu2, Najeeb Ullah Khan3
1Traditional Chinese Medicine Proctology Department, West China Hospital of Sichuan University-Ziyang Hospital (Ziyang Central Hospital), Ziyang City, 641300, China. zy578992933@sina.com.
BMC gastroenterology
|August 23, 2025
まとめ
グルカゴン類ペプチド-1受容体アゴニスト (GLP- 1 RAs) は,2型糖尿病患者の大腸がん (CRC) のリスクを増加させる可能性があります. この関連性を確認し,臨床実践を導くためにさらなる研究が必要である.
科学分野:
- 内分泌学
- 腫瘍学
- 薬理学について
背景:
- グルカゴン型ペプチド-1受容体アゴニスト (GLP- 1 RAs) は,2型糖尿病 (T2DM) と肥満に対して広く処方されています.
- 血糖コントロールと心臓血管の健康に有益ですが,がんのリスク,特に大腸がん (CRC) の増加との関連性について懸念があります.
研究 の 目的:
- GLP-1受容体アゴニスト (GLP-1RA) の使用と結腸直腸癌 (CRC) の発症リスクとの関連を評価するメタ分析を行う.
主な方法:
- 2024年12月までの主要な電子データベースを検索して,PRISMAのガイドラインに準拠した体系的なレビューとメタ分析が行われました.
- T2DM患者におけるCRCリスクに対するGLP-1RAの影響を評価した500万人以上の患者による7つの遡及コホート研究が含まれた.
- 質の評価には,ランダム効果モデルとI2統計を用いてニューカッスル・オタワスケールを使用し,総合分析と異質性の評価を行いました.
主要な成果:
- 7つの研究を総合した分析では,GLP-1RAを使用した患者のCRCのリスクが有意に増加していることが示された (RR,2. 31;95%CI,1. 8~2. 93).
- しかし,CRCの発生率は,他の薬剤と比較してGLP- 1 RA使用と有意に関連していなかった (OR,1. 73; 95%CI: 0. 21 - 14. 18).
- 品質評価は,含まれた遡及コホート研究において,偏差のリスクが低から中等であることが明らかになった.
結論:
- このメタ解析は,GLP-1 RAの使用と関連した大腸がんのリスクが著しく高まっていることを示唆している.
- 増加したリスクにもかかわらず,CRCの全体的な発生率はかなり高いとは考えられません.
- さらに大規模な長期臨床試験は,GLP- 1 RAsとがんリスクとの関係を完全に明らかにし,臨床処方決定に情報を提供するために正当化されています.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
400
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
400
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
256
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
610
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
610


